Two-Year Commitment will Inspire the Next Generation of Scientific Innovators Through AI-Enabled Research in Healthcare and Drug Discovery
HYDERABAD, India, July 31, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of the first Amgen Scholars Program in India at the International Institute of Information Technology Hyderabad (IIIT Hyderabad), bringing the globally respected undergraduate summer research program to India for the first time.
Supported through a two-year commitment from Amgen through summer 2027, the program reflects the company’s long-standing commitment to advancing science education and inspiring future innovators. The inaugural cohort comprises 10 undergraduate scholars, including students from India, Vietnam, Qatar, and Dubai, creating opportunities for scientific collaboration and exchange across Asia. The students represent universities across Asia and are pursuing undergraduate programs in science, engineering, and related disciplines, reflecting the program’s regional diversity and academic excellence.
As part of the intensive two-month residential research experience, students will explore artificial intelligence and machine learning applications in fundamental sciences, drug design and discovery, healthcare, cheminformatics, genomics and related areas alongside faculty mentors at IIIT Hyderabad. They will also have an opportunity to participate in seminars, networking events and a regional Amgen Scholars Symposium to be held in Tokyo in August 2026. At the conclusion of the program, each scholar presents their research through a scientific poster presentation. The scholars were selected through a rigorous evaluation by an expert committee at IIIT Hyderabad based on academic excellence, research aptitude, motivation for doctoral studies, and demonstrated interest in applying AI and machine learning to drug discovery.
“Scientific breakthroughs begin with curious minds and meaningful opportunities to learn,” said Naveen Gullapalli, Managing Director, Amgen India. “We are proud to bring the Amgen Scholars Program to India. We hope to inspire talented students to pursue research careers while helping build the interdisciplinary skills needed to strengthen India’s scientific ecosystem.”
“We are delighted to serve as the host institution for the first Amgen Scholars Program in India,” said Deva Priyakumar, Professor & Dean (R&D), IIIT Hyderabad. “The program aligns well with our research-led approach to education and provides undergraduate students with an exceptional opportunity to contribute to cutting-edge research in AI for healthcare and drug discovery while learning from leading faculty.”
“AI is transforming every stage of biotech research, from understanding disease biology to discovering new medicines,” said Sandeep Shukla, Professor & Director, IIIT Hyderabad. “This program gives students an opportunity to work on real scientific problems while developing the interdisciplinary research skills needed to address tomorrow’s complex healthcare challenges.”
Designed to inspire the scientists of tomorrow, the Amgen Scholars Program is a long-standing, signature initiative of the Amgen Foundation, providing undergraduates the opportunity to engage in a compelling summer, scientific research experience at some of the world’s leading institutions. This program builds on successful programming in the United States, with over 4,000 U.S. students having benefited from the program. Twenty-six leading institutions across the world currently host the summer research program. More than 6,000 students from over 1,000 colleges and universities have participated to date. Financial support for students is a critical component of the program, which seeks to ensure that eligible students, regardless of their financial status, can participate. The Amgen Scholars Program seeks to expand research, learning and networking opportunities for students committed to pursuing advanced degrees in STEM. Thousands of program alumni have gone on to complete graduate education and build careers across academia, biotechnology and healthcare in more than 40 countries. www.amgenscholars.com.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.
More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.
Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.
For more information about the Amgen Foundation, visit www.amgenfoundation.org
About IIIT Hyderabad
The International Institute of Information Technology, Hyderabad (IIIT-H) is an autonomous research university founded in 1998 that focuses on the core areas of Information Technology, such as Computer Science, Electronics and Communications, and their applications in other domains through inter-disciplinary research that has a greater social impact. Some of its research domains include Technology Innovation, Intelligent Systems, Signal Processing and Communications, Data Sciences, Language Technologies, Robotics, Security, Algorithms, Software Engineering, Visual Information Technology, VLSI and Embedded Systems Technology , Computer Systems, Machine Learning, Quantum Science and Technology, Computational Social Science, Cognitive Science, Computational Natural Sciences and Bioinformatics, Earthquake Engineering, Human Sciences, Spatial Informatics, Innovation and Entrepreneurship, Smart Cities, Artificial Intelligence, Digital Technologies in Healthcare and Biomedical Research.
Website: www.iiit.ac.in
Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon’s business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed, and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful, and may result in unanticipated costs, delays or failures to realize the benefits of the transactions. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/first-amgen-scholars-program-in-india-launches-at-iiit-hyderabad-302839774.html
